Elsalys Biotech :THE TYROMAB CONSORTIUM, HEADED BY ELSALYS BIOTECH, OBTAINS 1.57 MILLION EUROS FROM THE SINGLE INTERMINISTERIAL FUND (FUI)
September 11, 2015 04:14 ET
|
Elsalys Biotech
THE TYROMAB CONSORTIUM, HEADED BY
ELSALYS BIOTECH, OBTAINS 1.57 MILLION EUROS
FROM THE SINGLE INTERMINISTERIAL FUND (FUI)
Supported by ElsaLys Biotech, PX'Therapeutics, a subsidiary...
Elsalys Biotech :THE TYROMAB CONSORTIUM, HEADED BY ELSALYS BIOTECH, OBTAINS 1.57 MILLION EUROS FROM THE SINGLE INTERMINISTERIAL FUND (FUI)
September 11, 2015 04:08 ET
|
Elsalys Biotech
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
THE TYROMAB CONSORTIUM, HEADED BY ...
Elsalys Biotech : LE CONSORTIUM TYROMAB, DONT ELSALYS BIOTECH EST LE CHEF DE FILE, OBTIENT 1,57 MILLION D'EUROS DU FONDS UNIQUE INTERMINISTÉRIEL
September 11, 2015 04:08 ET
|
Elsalys Biotech
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
LE CONSORTIUM TYROMAB, DONT ELSALYS...
Elsalys Biotech acquires a first-in-class antibody with a dual biological mechanism of action: anti-angiogenic and immuno-modulator
July 02, 2015 05:17 ET
|
Elsalys Biotech
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Elsalys Biotech acquires a...